Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04906096 · ClinicalTrials.gov registry record · Phase 2
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
A Phase 2 study of Primary Central Nervous System Lymphoma and Non-Hodgkin Lymphoma of Extranodal Site, sponsored by Lakshmi Nayak, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT04906096 is a Phase 2 study of Primary Central Nervous System Lymphoma and Non-Hodgkin Lymphoma of Extranodal Site that is actively recruiting participants, run by Lakshmi Nayak, MD. The registered enrollment target is 25 participants, below the 51-participant average among 12 other Primary Central Nervous System Lymphoma trials with a reported enrollment target (51% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04906096, a Phase 2 study of Primary Central Nervous System Lymphoma and Non-Hodgkin Lymphoma of Extranodal Site, is actively recruiting participants, sponsored by Lakshmi Nayak, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)
Conditions Studied
Interventions
- DRUG PAXALISIB
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04906096
The ClinicalTrials.gov registry entry for NCT04906096 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 51-participant average among 12 other Primary Central Nervous System Lymphoma trials with a reported enrollment target (51% lower). The listed sponsor is Lakshmi Nayak, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Primary Central Nervous System Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which PAXALISIB is the first listed.
NCT04906096 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04906096 about?
NCT04906096 is a clinical study titled "Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL". This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)
What is the current status of trial NCT04906096?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-06-01. Estimated completion is 2027-12-01.
What conditions does trial NCT04906096 study?
This clinical trial studies the following conditions: Primary Central Nervous System Lymphoma, Non-Hodgkin Lymphoma of Extranodal Site.
What interventions are being tested in trial NCT04906096?
The interventions under investigation include: PAXALISIB (DRUG).
Who is sponsoring clinical trial NCT04906096?
This trial is sponsored by Lakshmi Nayak, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04906096 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Central Nervous System Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
RECRUITING · Phase 2
-
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
RECRUITING · Phase 2
-
Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
COMPLETED · Phase 2
-
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
RECRUITING · Phase 1
-
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
RECRUITING · Phase 1
-
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Primary Central Nervous System Lymphoma
All registered trials for this condition
Non-Hodgkin Lymphoma of Extranodal Site
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.